Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases

Bibliography

• Nahata MC. Lack of pediatric drug formulations. Pediatrics 1999;104(Suppl 3):607-9
   PubMed Web of Science ®Google Scholar
• Nahata MC, Allen LV Jr. Extemporaneous drug formulations. Clin Ther 2008;30:2112-19
   PubMed Web of Science ®Google Scholar
• Wilson JT. An update on the therapeutic orphan. Pediatrics 1999;104:585-90
   PubMed Web of Science ®Google Scholar
• van Riet-Nales DA, Schobben AF, Egberts TC, Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: a systematic literature review. Clin Ther 2010;32:924-38
   PubMed Web of Science ®Google Scholar
• Neubert A, Wong IC, Bonifazi A, Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. Pharmacol Res 2008;58:316-22
   PubMed Web of Science ®Google Scholar
• Tuleu C, Arenas-Lopez S, Robinson C, ‘Poppy seeds' in stomach aspirates: is oral omeprazole extemporaneous dispersion bioavailable? Eur J Pediatr 2008;167:823-5
   PubMed Web of Science ®Google Scholar
• Kairuz TE, Gargiulo D, Bunt C, Quality, safety and efficacy in the 'off-label' use of medicines. Curr Drug Saf 2007;2:89-95
   PubMedGoogle Scholar
• Conroy S. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr 2003;92:408-11
   PubMed Web of Science ®Google Scholar
• Standing JF, Tuleu C. Paediatric formulations—getting to the heart of the problem. Int J Pharm 2005;300:56-66
   PubMed Web of Science ®Google Scholar
• Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf 2002;25:1-5
   PubMed Web of Science ®Google Scholar
• Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005;59:674-6
   PubMed Web of Science ®Google Scholar
• Schirm E, Tobi H, de Vries TW, Lack of appropriate formulations of medicines for children in the community. Acta Paediatr 2003;92:1486-9
   PubMed Web of Science ®Google Scholar
• Milne CP, Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clin Ther 2008;30:2133-45
   PubMed Web of Science ®Google Scholar
• Zisowsky J, Krause A, Dingemanse J. Drug development for pediatric populations: regulatory aspects. Pharmaceutics 2010;2:364-88
   PubMedGoogle Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW. Developmental pharmacology - Drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-67
   PubMed Web of Science ®Google Scholar
• ICH E 11 Clinical investigation of medicinal products in the paediatric population. Published in the UK in: EU: note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99). London, 2000; and in the US in: US: International Conference on Harmonisation. Guidance on E 11 clinical investigation of medicinal products in pediatric population; Notice. Fed Regist 2000;65:78493-4
   PubMedGoogle Scholar
• Bowles A, Keane J, Ernest T, Specific aspects of gastro-intestinal transit in children for drug delivery design. Int J Pharm 2010;395:37-43
   PubMed Web of Science ®Google Scholar
• Formulations of choice for the paediatric population, committee for medicinal products for human use, EMA (London 23 June 2005 EMEA/CHMP/PEG/194810/2005). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003782.pdf [Last accessed 25 November 2011]
   Google Scholar
• Draft Guideline on pharmaceutical development of medicines for paediatric use, EMA (London 19 May 2011 EMA/CHMP/QWP/180157/2011). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/06/WC500107908.pdf [Last accessed 25 November 2011]
   Google Scholar
• Sosnik A, Carcaboso AM, Glisoni RJ, New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev 2010;62:547-59
   PubMed Web of Science ®Google Scholar
• Sosnik A, Chiappetta DA, Carcaboso AM. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J Control Release 2009;138:2-15
   PubMed Web of Science ®Google Scholar
• das Neves J, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev 2010;62:458-77
   PubMed Web of Science ®Google Scholar
• Romero EL, Morilla MJ. Nanotechnological approaches against Chagas disease. Adv Drug Deliv Rev 2010;62:576-88
   PubMed Web of Science ®Google Scholar
• Make medicines child size. World Health Organization, 2007. Available from: www.who.int/childmedicines/en/ [Last accessed 10 October 2011]
   Google Scholar
• Osuntokun B. Clinical trials in pediatrics: the drug delivery dimension. Adv Drug Deliv Rev 2006;58:90-105
   PubMed Web of Science ®Google Scholar
• Chappuy H, Doz F, Blanche S, Parental consent in paediatric clinical research. Arch Dis Child 2006;91:112-16
   PubMed Web of Science ®Google Scholar
• Gans-Brangs KR, Plourde PV. The evolution of legislation to regulate pediatric clinical trials: present and continuing challenges. Adv Drug Deliv Rev 2006;58:106-15
   PubMed Web of Science ®Google Scholar
• Pal V, Nahata ME. Need for extemporaneous formulations in pediatric patients. J Pediatr Pharmacol Ther 2001;6:107-19
   Google Scholar
• Stoyanova-Beninska VV, Wohlfarth T, Isaac M, The EU paediatric regulation: effects on paediatric psychopharmacology in Europe. Eur Neuropsychopharmacol 2011;21:565-70
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Kearns P, Caron H, The role of the ‘innovative therapies for children with cancer' (ITCC) European consortium. Cancer Treat Rev 2010;36:328-34
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E. Drug policy in Europe Research and funding in neonates: current challenges, future perspectives, new opportunities. Early Hum Dev 2011;87:S27-30
   PubMed Web of Science ®Google Scholar
• Breitkreutz J. European perspectives on pediatric formulations. Clin Ther 2008;30:2146-54
   PubMed Web of Science ®Google Scholar
• Strickley RG, Iwata Q, Wu S, Pediatric drugs – review of commercially available oral formulations. J Pharm Sci 2008;97:1731-74
   PubMed Web of Science ®Google Scholar
• Zuccotti GV, Fabiano V. Safety issues with ethanol as an excipient in drugs intended for pediatric use. Expert Opin Drug Saf 2011;10:499-502
   PubMed Web of Science ®Google Scholar
• Giacoia GP, Taylor-Zapata P, Mattison D. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups. Clin Ther 2008;30:2097-101
   PubMed Web of Science ®Google Scholar
• European Paediatric Formulation Initiative. Available from: www.eupfi.org [Last accessed 10 October 2011]
   Google Scholar
• Cram A, Breitkreutz J, Desset-Brethes S, Challenges of developing palatable oral paediatric formulations. Int J Pharm 2009;365:1-3
   PubMed Web of Science ®Google Scholar
• Neonatal European Information System. Available from: www.euroneostat.org [Last accessed 10 October 2011]
   Google Scholar
• Lavelle EC, Sharif S, Thomas NW, The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv Drug Deliv Rev 1995;18:5-22
   Web of Science ®Google Scholar
• AIDS epidemic update 2007, World Health Organization. Available from: www.who.int/hiv/epiupdates/en/index.html [Last accessed 11 November 2010]
   Google Scholar
• Giaquinto C, Morelli E, Fregonese F, Current and future antiretroviral treatment options in paediatric HIV infection. Clin Drug Investig 2008;28:375-97
   PubMed Web of Science ®Google Scholar
• Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med 2010;61:169-85
   PubMed Web of Science ®Google Scholar
• Sosnik A, Amiji M. Nanotechnology solutions for infectious diseases in developing nations. Adv Drug Deliv Rev 2010;62:375-7
   PubMed Web of Science ®Google Scholar
• Sosnik A. Nanotechnology contributions to the pharmacotherapy of pediatric HIV: a dual scientific and ethical challenge and a still pending agenda. Nanomedicine (UK) 2010;5:833-7
   PubMed Web of Science ®Google Scholar
• Waning B, Diedrichsen E, Jambert E, The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children. BMC Pediatr 2010;10:74
   PubMed Web of Science ®Google Scholar
• Chang R, Guo X, Burnside B, A review of fast dissolving tablets. Pharm Tech 2000;12:52-8
   Google Scholar
• Siddiqui N, Garg G, Sharma PK. Fast dissolving tablets: preparation, characterization and evaluation: an overview. Int J Pharm Sci Rev Res 2010;4:87-96
   Google Scholar
• Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: a review. Trop J Pharm Res 2009;8:161-72
   Web of Science ®Google Scholar
• Sumiya K, Baba Y, Inomata S, Preparation and clinical evaluation of orally-disintegrating clonidine hydrochloride tablets for preanesthetic medication. Yakugaku Zasshi 2000;120:652-6
   PubMed Web of Science ®Google Scholar
• Homma M, Sumiya K, Kambayashi Y, Assessment of clonidine orally disintegrating tablet for pre-anesthetic medication in pediatric surgery. Biol Pharm Bull 2006;29:321-3
   PubMed Web of Science ®Google Scholar
• Singh J, Philip AK, Pathak K. Optimization studies on design and evaluation of orodispersible pediatric formulation of indomethacin. AAPS PharmSciTech 2008;9:60-6
   PubMed Web of Science ®Google Scholar
• Patil C, Das S. Effect of various superdisintegrants on the drug release profile and disintegration time of lamotrigine orally disintegrating tablets. Afr J Pharm Pharmacol 2011;5:76-82
   Web of Science ®Google Scholar
• Thakur RR, Casi M. An unlimited scope for novel formulations as orally disintegrating systems: present and future prospects. J Appl Pharm Sci 2011;1:13-19
   Google Scholar
• Akbari BV, Dholakiya RB, Shiyani BG, Design, development and characterization of mouth dissolving tablets of cinnarizine using super-disintegrants. Int J PharmTech Res 2010;2:97-105
   Google Scholar
• Gandhi GS, Mundhada DR, Bhaskaran S. Levocetirizine orodispersible tablet by direct compression method. J Appl Pharm Sci 2011;5:145-50
   Google Scholar
• Bowen A, Palasanthiran P, Sohn AH. Global challenges in the development and delivery of paediatric antiretrovirals. Drug Discov Today 2008;13:530-5
   PubMed Web of Science ®Google Scholar
• Kayitare E, Vervaet C, Ntawukulilyayo JD, Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications. Int J Pharm 2009;370:41-6
   PubMed Web of Science ®Google Scholar
• Padmavathi Y, Madhava Reddy B, Amareswar P. Development of fixed dose combination dispersible tablets containing stavudine, lamivudine and nevirapine for paediatric applications. Int J Pharm Technol 2011;3:2343-52
   Google Scholar
• Pensi T. Fixed-dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV-infection: a preliminary report. Indian Pediatr 2007;44:519-21
   PubMed Web of Science ®Google Scholar
• Stoltenberg I, Winzenburg G, Breitkreutz J. Solid oral dosage forms for children - Formulations, excipients and acceptance issues. Eur Ind Pharm 2011;8:4-7
   Google Scholar
• Badgujar BP, Mundada AS. The technologies used for developing orally disintegrating tablets: a review. Acta Pharm 2011;61:117-39
   PubMed Web of Science ®Google Scholar
• Siewert M, Dressman J, Brown CK, FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech 2003;4:E7
   PubMedGoogle Scholar
• Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release 2009;139:94-107
   PubMed Web of Science ®Google Scholar
• Gavaskar B, Kumar SV, Sharan G, Overview on fast dissolving films. Int J Pharm Pharm Sci 2010;2:29-33
   Google Scholar
• Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004;3:785-96
   PubMed Web of Science ®Google Scholar
• Chan H-K, Kwok PCL. Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliv Rev 2011;63:406-16
   PubMed Web of Science ®Google Scholar
• Sharma P, Garg S. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Deliv Rev 2010;62:491-502
   PubMed Web of Science ®Google Scholar
• Van Gyseghem E, Pendela M, Baert L, Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies. Eur J Pharm Biopharm 2008;70:853-60
   PubMed Web of Science ®Google Scholar
• Sosnik A, Carcaboso AM, Chiappetta DA. Polymeric nanocarriers: new endeavors for the optimization of the technological aspects of drugs. Recent Pat Biomed Eng 2010;1:43-59
   Google Scholar
• Chiappetta DA, Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. Eur J Pharm Biopharm 2007;66:303-17
   PubMed Web of Science ®Google Scholar
• Gaucher G, Satturwar P, Jones MC, Polymeric micelles for oral drug delivery. Eur J Pharm Biopharm 2010;76:147-58
   PubMed Web of Science ®Google Scholar
• Brichard B, Van der Linden D. Clinical practice treatment of HIV infection in children. Eur J Pediatr 2009;168:387-92
   PubMed Web of Science ®Google Scholar
• Rabel SR, Patel M, Sun S. Electronic and resonance effects on the ionization of structural analogues of efavirenz. AAPS PharmSci 2001;3:E28
   PubMedGoogle Scholar
• Gao JZh, Hussain MA, Motheram R, Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (Efavirenz). J Pharm Sci 2007;96:2970-7
   PubMed Web of Science ®Google Scholar
• Friedland G, Khoo S, Jack C, Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006;58:1299-302
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Di Giambenedetto S, Bracciale L, Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother 2009;64:109-17
   PubMed Web of Science ®Google Scholar
• ter Heine R, Scherpbier HJ, Crommentuyn KM, A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antiv Ther 2008;13:779-87
   PubMed Web of Science ®Google Scholar
• Csajka C, Marzolini C, Fattinger K, Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003;73:20-30
   PubMed Web of Science ®Google Scholar
• Bahal SM, Romansky JM, Alvarez FJ. Medium chain triglycerides as vehicle for palatable oral liquids. Pharm Dev Technol 2003;8:111-15
   PubMed Web of Science ®Google Scholar
• Sellers RS, Antman M, Phillips J, Effects of Miglyol 812 on rats after 4 weeks of gavage as compared with methylcellulose/Tween 80. Drug Chem Toxicol 2005;28:423-32
   PubMed Web of Science ®Google Scholar
• Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 2007;4:37-45
   PubMed Web of Science ®Google Scholar
• Fabiano V, Mameli C, Zuccotti GV. Paediatric pharmacology: remember the excipients. Pharmacol Res 2011;63:362-5
   PubMed Web of Science ®Google Scholar
• Medecins Sans Frontieres. Essential Medicines List, 17th WHO Meeting. Letter to WHO Expert Committee on Essential Medicine Selection. Geneva 2009. Available from: www.who.int/selection_medicines/committees/expert/17/en/index.html [Last accessed 8 August 2011]
   Google Scholar
• Sosnik A, Chiappetta DA, Hocht C. Composiciones farmaceuticas en forma de soluciones acuosas destinadas a la administracion oral de agentes antirretrovirales. AR072715; 2009
   Google Scholar
• Chiappetta DA, Hocht C, Taira C, Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailaibility. Nanomedicine (UK) 2010;5:11-23
   PubMed Web of Science ®Google Scholar
• Chiappetta DA, Hocht C, Taira C, Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. Biomaterials 2011;32:2379-87
   PubMed Web of Science ®Google Scholar
• Chiappetta DA, Hocht C, Sosnik A. A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate paediatric management of the anti-HIV therapy. Curr HIV Res 2010;8:223-31
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Yogev R, Arguedas A, Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Antimicrob Agents Chemother 2009;53:1912-20
   PubMed Web of Science ®Google Scholar
• Blumer J, Rodriguez A, Sanchez PJ, Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. Antimicrob Agents Chemother 2010;54:2032-41
   PubMed Web of Science ®Google Scholar
• Limayem Blouza I, Charcosset C, Sfar S, Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use. Int J Pharm 2006;325:124-31
   PubMed Web of Science ®Google Scholar
• Shafiq S, Shakeel F, Talegaonkar S, Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 2007;66:227-43
   PubMed Web of Science ®Google Scholar
• Mishra B, Sahoo BL, Mishra M, Design of a controlled release liquid formulation of lamotrigine. DARU 2011;19:126-37
   PubMed Web of Science ®Google Scholar
• Maurer BJ, Kalous O, Yesair DW, Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res 2007;13:3079-86
   PubMed Web of Science ®Google Scholar
• Schiffman SS, Zervakis J, Heffron S, Effect of protease inhibitors on the sense of taste. Nutrition 1999;15:767-72
   PubMed Web of Science ®Google Scholar
• Dhoka MV, Nimbalkar UA, Pande A. Preparation of Cefpodoxime Proxetil-polymeric microspheres by the emulsion solvent diffusion method for taste masking. Int J PharmTech Res 2011;3:411-19
   Google Scholar
• Martinez BL, Riordan FAI. Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children. HIV/AIDS - Res Palliative Care 2010;2:59-67
   Google Scholar
• Akbari BV, Patel BP, Dholakiya RB, Development and evaluation of taste masked suspension of prokinetic agent by using ion exchange resin. Int J PharmTech Res 2010;2:240-5
   Google Scholar
• Chiappetta DA, Carcaboso AM, Bregni C, Indinavir-loaded pH-sensitive microparticles for taste masking: toward extemporaneous paediatric HIV/AIDS liquid formulations with improved patient compliance. AAPS PharmSciTech 2009;10:1-6
   PubMed Web of Science ®Google Scholar
• Matsui D. Assessing the palatability of medications in children. Paediatr Perinat Drug Ther 2007;8:55-60
   Google Scholar
• Woertz K, Tissen C, Kleinebudde P, Rational development of taste masked oral liquids guided by an electronic tongue. Int J Pharm 2010;400:114-23
   PubMed Web of Science ®Google Scholar
• WHO. WHO expert working group meeting to determine preferred ARV medicines for treating and preventing HIV infection in younger children. Geneva. October 23-25, 2006. Available from: www.who.int/hiv/events/paediatricmeetingreport.pdf [Last accessed 25 November 2009]
   Google Scholar
• Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 2005;11:S33-44
   PubMed Web of Science ®Google Scholar
• Frieden TR, Sterling TR, Munsiff SS, Tuberculosis (Seminar). Lancet 2003;362:887-99
   PubMed Web of Science ®Google Scholar
• Onyebujoh P, Zumla A, Ribeiro I, Treatment of tuberculosis: present status and future prospects. Bull World Health Organ 2005;83:857-65
   PubMed Web of Science ®Google Scholar
• WHO, Treatment of tuberculosis: guidelines for national programmes. 3rd edition. World Health Organization; Geneva: 2003
   Google Scholar
• Dye C. Global epidemiology of tuberculosis. Lancet 2006;367:938-40
   PubMed Web of Science ®Google Scholar
• Brewer T, Heymann S. Long time due: reducing tuberculosis mortality in the 21st century. Arch Med Res 2005;36:617-21
   PubMed Web of Science ®Google Scholar
• WHO list of prequalified medicinal products. Available from: http://apps.who.int/prequal/query/ProductRegistry.aspx?list=tb [Last accessed 22 November 2011]
   Google Scholar
• Shukla V, Nanjawade BK, Manvi FV, Effect of different superdisintegrants on release behavior of rifampicin dispersible tablets for oral treatment of tuberculosis. Int J Pharm Sci 2010;2:871-83
   Google Scholar
• Shukla V, Manvi FV. Effect of Kollidon Cl on release behavior of isoniazid and rifampicin combination dispersible tablets for oral treatment of tuberculosis. Int J Drug Devel Res 2010;2:892-906
   Google Scholar
• Reverchon E, De Marco I, Della Porta G. Rifampicin microparticles production by supercritical antisolvent precipitation. Int J Pharm 2002;243:83-91
   PubMed Web of Science ®Google Scholar
• Moretton MA, Glisoni RJ, Chiappetta DA, Sosnik A. Molecular implications in the nanoencapsulation of the antituberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf B Biointerfaces 2010;79:467-79
   PubMed Web of Science ®Google Scholar
• Moretton MA, Chiappetta DA, Sosnik A. Cryoprotection-lyophilisation and physical stabilization of rifampicin-loaded flower-like polymeric micelles. J Royal Soc-Interface; doi: 10.1098/rsif.2011.0414
   PubMed Web of Science ®Google Scholar
• Moretton MA, Chiappetta DA, Sosnik A. Molecular implications of the encapsulation and chemical stabilization of rifampicin in flower-like polymeric micelles. I Argentine Symposium of Nanomedicines; October 2011; Buenos Aires, Argentina
   Google Scholar
• Pandey R, Zahoor A, Sharma S. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 2003;83:373-8
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis 2005;85:415-20
   PubMed Web of Science ®Google Scholar
• Swai H, Semete B, Kalombo L, Potential of treating tuberculosis with a polymeric nano-drug delivery system. J Control Release 2008;132:e48
   Web of Science ®Google Scholar
• Santos-Magalhaes NS, Mosqueira VC. Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev 2010;62:560-75
   PubMed Web of Science ®Google Scholar
• Malaria fact sheet. World Health Organization. Available from: www.who.int/mediacentre/factsheets/fs094/en/index.html [Last accessed 12 July 2011]
   Google Scholar
• Kurth F, Belard S, Adegnika AA, Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infect Dis 2010;10:125-32
   PubMed Web of Science ®Google Scholar
• WHO. World Malaria Report 2008. Geneva: World Health Organization, 2008. Available from: http://www.who.int/malaria/publications/atoz/9789241563697/en/index.html [Last accessed 22 Dec 2009]
   Google Scholar
• Salah MT, Faroug M, Magzoub MM, Efficacy of artemether-lumfantrine (Co-Artesiane®) suspension in the treatment of uncomplicated Plasmodium falciparum malaria among children under 5 years in eastern Sudan. Trop J Pharm Res 2006;5:551-5
   Google Scholar
• Abdulla S, Sagara I, Borrmann S, Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single- blind, multicentre trial. Lancet 2008;372:1819-27
   PubMed Web of Science ®Google Scholar
• Juma EA, Obonyo CO, Akhwale WS, A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya. Malar J 2008;7:262
   PubMedGoogle Scholar
• Ramharter M, Kurth F, Schreier AC, Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis 2008;198:911-19
   PubMed Web of Science ®Google Scholar
• Bouyou-Akotet MK, Ramharter M, Ngoungou EB, Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon. Wien Klin Wochenschr 2010;122:173-8
   PubMed Web of Science ®Google Scholar
• Bouyou-Akotet MK, Ramharter M, Ngoungou EB, Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon. Wien Klin Wochenschr 2010;122:173-8
   PubMed Web of Science ®Google Scholar
• Abdulla S, Sagara I. Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children. Malar J 2009;8(Suppl 1):S7
   PubMed Web of Science ®Google Scholar
• Abdulla S, Amuri B, Kabanywanyi A, Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Malar J 2010;9:253-61
   PubMedGoogle Scholar
• Krause J, Thommes M, Breitkreutz J. Immediate release pellets with lipid binders obtained by solvent-free cold extrusion. Eur J Pharm Biopharm 2009;71:138-44
   PubMed Web of Science ®Google Scholar
• Breitkreutz J, Bornhoft M, Woll F, Pediatric drug formulations of sodium benzoate: I. Coated granules with a hydrophilic binder. Eur J Pharm Biopharm 2003;56:247-53
   PubMed Web of Science ®Google Scholar
• Breitkreutz J, El-Saleh F, Kiera C, Pediatric drug formulations of sodium benzoate: II. Coated granules with a lipophilic binder. Eur J Pharm Biopharm 2003;56:255-60
   PubMed Web of Science ®Google Scholar
• Kayumba PC, Huyghebaert N, Cordella C, Quinine sulphate pellets for flexible pediatric drug dosing: formulation development and evaluation of taste-masking efficiency using the electronic tongue. Eur J Pharm Biopharm 2007;66:460-5
   PubMed Web of Science ®Google Scholar
• Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007;59:645-66
   PubMed Web of Science ®Google Scholar
• Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008;36:30-42
   PubMed Web of Science ®Google Scholar
• Shah PP, Mashru RC. Palatable reconstitutable dry suspension of artemether for flexible pediatric dosing using cyclodextrin inclusion complexation. Pharm Dev Technol 2010;15:276-85
   PubMed Web of Science ®Google Scholar
• Shah PP, Mashru RC. Formulation and evaluation of taste masked oral reconstitutable suspension of primaquine phosphate. AAPS PharmSciTech 2008;9:1025-30
   PubMed Web of Science ®Google Scholar
• Shabir A, Mohammed A. Exploring the use of cyclodextrins as carriers in paediatric formulations. British J Clin Pharm 2010;2:275-8
   Google Scholar
• Pareek A, Nandy A, Kochar D, Efficacy and safety of beta-arteether and alpha/beta-arteether for treatment of acute Plasmodium falciparum malaria. Am J Trop Med Hyg 2006;75:139-42
   PubMed Web of Science ®Google Scholar
• Tripathi R, Khanna M, Dwivedi AK. Efficacy of novel oral formulations of alpha/beta arteether against multidrug-resistant malaria in mice. Chemother 2010;56:178-83
   PubMed Web of Science ®Google Scholar
• Semwal R, Semwal DK, Badoni R. Chewing gum: a novel approach for drug delivery. J Appl Res 2010;10:124-33
   Google Scholar
• Rassing MR. Chewing gum as a drug delivery system. Adv Drug Deliv Rev 1994;13:89-121
   Web of Science ®Google Scholar
• Sjogren K, Birkhed D, Persson LG, Salivary fluoride clearance after a single intake of fluoride tablets and chewing gums in children, adults, and dry mouth patients. Scand J Dent Res 1993;101:274-8
   PubMedGoogle Scholar
• Stallergenes. Available from: http://www.stallergenes.com/fileadmin/images/corporate/gallery/Documents_pdf/2009-11-26-pil-oralair-300-en-clean.pdf [Last accessed 12 October 2011]
   Google Scholar
• American Academy of Pediatrics. Committee on drugs. Alternative routes of drug administration—advantages and disadvantages. Pediatrics 1997;100:143-52
   PubMed Web of Science ®Google Scholar
• Pires A, Fortuna A, Alves G, Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci 2009;12:288-311
   PubMed Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009;379:146-57
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99:1654-73
   PubMed Web of Science ®Google Scholar
• Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004;56:3-17
   PubMed Web of Science ®Google Scholar
• Mainardes RM, Khalil NM, Daflon Gremiao MO. Intranasal delivery of zidovudin by PLA and PLA–PEG blend nanoparticles. Int J Pharm 2010;395:266-71
   PubMed Web of Science ®Google Scholar
• Touitou E, Waknine JH, Godin B, Treatment of malaria in a mouse model by intranasal drug administration. Int J Parasitol 2006;36:1493-8
   PubMed Web of Science ®Google Scholar
• Vivithanaporn P, Gill MJ, Power C. Impact of current antiretroviral therapies on neuroAIDS. Expert Rev Anti Infect Ther 2011;9:371-4
   PubMed Web of Science ®Google Scholar
• Grovit-Ferbas K, Harris-White ME. Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction. Immunol Res 2010;48:40-58
   PubMed Web of Science ®Google Scholar
• Van Rie A, Mupuala A, Dow A. Children in Kinshasa, Democratic Republic of the Congo, Impact of the HIV/AIDS epidemic on the neurodevelopment of preschool-aged. Pediatrics 2008;122:e123
   PubMed Web of Science ®Google Scholar
• Chiappetta DA, Hocht C, Opezzo JAW, Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Submitted
   Google Scholar
• American Association for Respiratory Care (AARC) Clinical Practice Guideline. Selection of an aerosol delivery device for neonatal and pediatric patients. Respir Care 1995;40:1325-35
   PubMedGoogle Scholar
• NICE Technology Appraisal Guidance No. 10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. Nice: London 2000. Available from: http://www.nice.org.uk/nicemedia/pdf/NiceINHALERguidance.pdf [Last accessed 30 November 2011]
   Google Scholar
• NICE Technology Appraisal Guidance No. 38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5-15 years). Nice: London 2002. Available from: http://www.nice.org.uk/nicemedia/live/11450/32338/32338.pdf [Last accessed 30 November 2011]
   Google Scholar
• Guideline in the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary diseases (COPD). Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003551.pdf [Last accessed 12 October 2011]
   Google Scholar
• Mathias NR, Hussain MA. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci 2010;99:1-20
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004;54:761-6
   PubMed Web of Science ®Google Scholar
• Deol P, Khuller GK. Lung specific liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochem Biophys Acta 1997;1334:161-72
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 2005;55:430-5
   PubMed Web of Science ®Google Scholar
• Sharma R, Saxena D, Dwivedi AK, Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001;18:1405-10
   PubMed Web of Science ®Google Scholar
• Mizoe T, Ozeki T, Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS PharmSciTech 2008;9:755-61
   PubMed Web of Science ®Google Scholar
• Emami J, Hamishehkar H, Najafabadi AR, Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology. J Microencapsul 2009;26:1-8
   PubMed Web of Science ®Google Scholar
• Tsifansky MD, Yeo Y, Evgenov OV, Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J 2008;10:254-60
   PubMed Web of Science ®Google Scholar
• Muttil P, Kaur J, Kumar K, Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci 2007;32:140-50
   PubMed Web of Science ®Google Scholar
• Ohashi K, Kabasawa T, Ozeki T, One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J Control Release 2009;135:19-24
   PubMed Web of Science ®Google Scholar
• Ojewole E, Mackraj I, Naidoo P, Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm 2008;70:697-710
   PubMed Web of Science ®Google Scholar
• Taki H, Ogawa K, Nikai T. Pharmaceutical study of suppository formulations for improved in vivo kinetics of rifampicin. Kekkaku 2008;83:451-6
   PubMedGoogle Scholar
• Looareesuwan S, Wilairatana P, Vanijanonta S, Efficacy and tolerability of a sequential, artesunate suppository plus mefloquine, treatment of severe falciparum malaria. Ann Trop Med Parasitol 1995;89:469-75
   PubMed Web of Science ®Google Scholar
• WHO: Guidelines for the treatment of malaria, second edition, 2010. Available from: http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html [Last accessed 11 October 2011]
   Google Scholar
• Hinton RL, Auwun A, Pongua G, Caregivers' acceptance of using artesunate suppositories for treating childhood malaria in Papua New Guinea. Am J Trop Med Hyg 2007;76:634-40
   PubMed Web of Science ®Google Scholar
• Barnes KI, Mwenechanya J, Tembo M, Efficacy of rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria in African children and adults: a randomised study. Lancet 2004;363:1598-605
   PubMed Web of Science ®Google Scholar
• Pengsaa K, Sirivichayakul C, Na-Bangchang K, Life-saving rectal artesunate for complicated malaria in children. Southeast Asian J Trop Med Public Health 2005;36:597-601
   PubMedGoogle Scholar
• Gaudin K, Barbaud A, Boyer C, In vitro release and stability of an artesunate rectal gel suitable for pediatric use. Int J Pharm 2008;353:1-7
   PubMed Web of Science ®Google Scholar
• The removable ADHD patch for children and adolescents. Available from: http://www.daytrana.com/about-daytrana/adhd-patch-children.aspx [Last accessed 12 October 2011]
   Google Scholar
• Dubey V, Mishra D, Nahar M, Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes. Nanomedicine 2010;6:590-6
   PubMed Web of Science ®Google Scholar
• Romero EL, Morilla MJ. Drug delivery systems against leishmaniasis? Still an open question. Expert Opin Drug Deliv 2008;5:805-23
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008;26:1261-8
   PubMed Web of Science ®Google Scholar
• Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int J Pharm 2008;364:227-36
   PubMed Web of Science ®Google Scholar
• Shah UU, Roberts M, Orlu Gul M, Needle-free and microneedle drug delivery in children: a case for disease-modifying antirheumatic drugs (DMARDs). Int J Pharm 2011;416:1-11
   PubMed Web of Science ®Google Scholar
• Cazares-Delgadillo J, Ganem-Rondero A, Kalia YN. Human growth hormone: new delivery systems, alternative routes of administration, and their pharmacological relevance. Eur J Pharm Biopharm 2011;78:278-88
   PubMed Web of Science ®Google Scholar
• Dorr HG, Zabransky S, Keller E, Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle. J Pediatr Endocrinol Metab 2003;16:383-92
   PubMed Web of Science ®Google Scholar
• True AL, Chiu YY, Demasi RA, Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration. Pharmacotherapy 2006;26:1679-86
   PubMed Web of Science ®Google Scholar
• Jørgensen JT. A challenging drug development process in the era of personalized medicine. Drug Discov Today 2011;16:891-7
   PubMed Web of Science ®Google Scholar
• Salunke S, Hempenstall J, Kendall R, European Paediatric Formulation Initiative's (EuPFI) 2nd conference commentary—formulating better medicines for children. Int J Pharm 2011;419:235-9
   PubMed Web of Science ®Google Scholar
• Collins S. The antiretroviral pipeline. 2011 pipeline report, 2nd Edition, i-Base/The Treatment Action Group, pages 17-37. Available from: http://www.treatmentactiongroup.org/sites/tagone.drupalgardens.com/files/2011pipeline_0.pdf [Last accessed 5 December 2011]
   Google Scholar
• Clayden P. The pediatric antiretroviral pipeline. 2011 pipeline report, 2nd Edition, i-Base/The Treatment Action Group, pages 38-53. Available from: http://www.treatmentactiongroup.org/sites/tagone.drupalgardens.com/files/2011pipeline_0.pdf [Last accessed 5 December 2011]
   Google Scholar